logo-loader

Amryt Pharma PLC

Receive alerts
Market:
AIM
Market Cap:
£177.31 m
Price
116.00 GBX
Change
-2.11%
52 weeks high
143.00
52 weeks low
69.90

WHO WE ARE

We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare and orphan diseases.

We are building an exciting portfolio of breakthrough, proprietary medicines by looking beyond the ordinary and recognising potential, where others see none.

A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity and ethical practice. We aim to forge partnerships and collaborations that work for all. By listening to our stakeholders we create a clear path for our transformative medicines to reach those that need them.

OUR TEAM

At Amryt Pharma we have an exceptional team with the collective vision to deliver medicines that are truly transformative for people with rare, debilitating illnesses.

Our leadership team offers a wealth of experience in identifying, commercialising and delivering new treatments across global markets. Our ability to navigate diverse regulatory and reimbursement environments, combining a ‘think global, act local approach’, positions us optimally to deliver our goals.

PRODUCT PORTFOLIO

Amryt Pharma is committed to delivering safe, effective and innovative medicines that treat extremely rare and life-threatening diseases; transforming lives where it may not have been possible in the past. Our portfolio of specialist therapies includes products that we plan to make available to people with rare diseases across the world.

AP101 (OLEOGEL S-10)



AP101 (Oleogel S-10) is being developed as a prescription medicine for Epidermolysis Bullosa (EB), for which there are severely limited treatment options. It is currently in an investigational global Phase III clinical trial for this indication; however, it has already been approved in Europe for use in the treatment of partial thickness wounds (PTW) in adults.

It is a topical product, to be applied to the skin, incorporating a betulin-based active formulated with sunflower oil. AP101 causes the keratinocytes (cells that regenerate the outer layer of the skin) to migrate (move across the wound) and to differentiate into mature epithelial skin cells, thereby ensuring more rapid wound healing.

LOJUXTA®▼(LOMITAPIDE)



Lojuxta (lomitapide) capsules is a prescription medicine used along with diet and other lipid-lowering treatments, including low-density lipoprotein (LDL) apheresis where available, in adults with homozygous familial hypercholesterolaemia (HoFH).

Amryt Pharma holds an exclusive licence to sell lomitapide for adults across the EEA, Middle East, North Africa, Turkey and Israel.

Unlike other therapies, lomitapide does not work by trying to clear the high levels of cholesterol. It works by reducing the production and release of cholesterol from the liver and by reducing the absorption of cholesterol from the intestines following a meal. Specifically, lomitapide is a first in class oral, selective inhibitor of microsomal triglyceride transfer protein (MTP) a protein necessary for the proper assembly and secretion of apolipoprotein B (apo B)-containing lipoproteins in the liver and the intestines. Inhibition of MTP reduces lipoprotein secretion and circulating concentrations of lipoprotein‑borne lipids including cholesterol, LDL-C and triglycerides.

The European Commission (EC) granted authorisation for lomitapide under the trade name ‘Lojuxta’ in July 2013. Lojuxta is indicated as:

An adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinemia and secondary causes of hypercholesterolaemia (e.g., nephrotic syndrome, hypothyroidism) must be excluded.

AP102



AP102 is a somatostatin analogue treatment for acromegaly currently in pre-clinical development. Unlike other somatostatins analogues that are currently used to treat acromegaly patients for whom surgery is not an option, AP102 has a balanced, dual action specifically on somatostatin receptors 2 and 5 and has been observed in early research to reduce human pituitary growth hormone secretion while having little impact on blood sugar levels and propensity to cause diabetes.

These findings will be the subject of future research in human subjects to confirm the safety and efficacy of AP102 starting in 2018.

HARRY STRATFORD
Non-Executive Chairman (OBE)

Harry Stratford joined Amryt Pharma as Non-Executive Chairman in April 2016. He has over 40 years’ experience in the pharmaceutical industry, having built two successful, publicly listed pharmaceutical companies. In 1986, he founded Shire plc, where he was CEO for almost a decade. Under his leadership, Shire grew to become one of Europe’s largest specialty pharmaceutical companies and it is a constituent of the FTSE100 index. Following the success of Shire, Mr Stratford went on to found ProStrakan in 1995, another international specialty pharmaceutical company, where he was CEO, Executive Chairman and finally Non-Executive Chairman until his retirement in 2007. He holds a BSc. in Chemistry from the University of London and was awarded an OBE for his contribution to the Scottish Life Sciences Industry in the 2007 New Year’s Honours list.

 

DR. JOE WILEY
Chief Executive Officer (CEO)

Dr Joe Wiley co-founded Amryt Pharma in August 2015 and has over 20 years’ experience across the pharmaceutical, medical and venture capital industries. Previously, he opened and led Sofinnova Ventures’ European office, was medical director at Astellas Pharma, and held investment roles at Spirit Capital, Inventages Venture Capital and Aberdeen Asset Management (UK). Dr. Wiley trained in general medicine at Trinity College Dublin, specialising in neurology. He is a Member of the Royal College of Physicians of Ireland and has an MBA from INSEAD.

RORY NEALON
Chief Financial Officer and Chief Operating Officer (CFO & COO)

Rory Nealon co-founded Amryt Pharma in August 2015. Prior to that, he was the Chief Financial Officer (from 2003), Chief Operating Officer (from November 2007) and Board Member of Trinity Biotech plc, a diagnostic company listed on Nasdaq. He has also been a Board Member and Chief Financial Officer of Conduit plc, an Irish directory services provider with operations in Ireland, the UK, Austria and Switzerland, as well as an Associate Director at AIB Capital Markets, a subsidiary of AIB Group plc, the Irish banking group. He holds a Bachelor of Commerce degree from University College Dublin, is a Fellow of the Institute of Chartered Accountants in Ireland, a member of the Institute of Taxation in Ireland and a member of the Institute of Corporate Treasurers in the UK.

RAY STAFFORD
Non-Executive Director

Ray Stafford has worked in the pharmaceutical industry for 30 years and joined the Amryt Pharma Board of Directors in April 2016. He held a number of senior positions, including those of CEO and Chairman, and was a majority shareholder at Tosara Group, which owned, manufactured and marketed the successful international brand Sudocrem. He was also previously the CEO of Forest UK and Ireland, and then Forest Europe. Separately, Mr Stafford founded what is, today, one of Ireland’s leading multi-channel sales, marketing and distribution service providers, approved by the Irish Medicines Board to service the wholesale and retail trade.

JAMES CULVERWELL
Non-Executive Director

James Culverwell joined Amryt Pharma as a Non-Executive Director in April 2016. He has over 30 years’ experience in analysing and valuing pharmaceutical companies, having held senior positions at several leading finance institutions, including Hoare Govett and Merrill Lynch, where he was Head of European Pharmaceutical Equity Research. In 2004, Mr Culverwell set up Sudbrook Associates, a healthcare corporate advisory company, and he currently sits on the Boards of four other pharmaceutical companies. He has an MSc from the University of Aberdeen.

MARKUS ZIENER
Non-Executive Director

Markus Ziener joined Software AG Stiftung (a major shareholder in Amryt Pharma) in 2013 as Director of Asset Management, before becoming Chief Financial Officer in August 2014. Prior to this, he worked in a number of senior roles across a broad range of industries, including as Managing Director of Handelskontor Willmann für Naturprodukte and as CEO of GeckoGroup AG wetzlar Vorstand.

 

CONTACT US

MEDICAL ENQUIRES

[email protected]

INVESTOR RELATIONS ENQUIRES
[email protected]

BUSINESS DEVELOPMENT ENQUIRIES
[email protected]

BUSINESS MEDIA AND ANALYST ENQUIRIES
[email protected]

GENERAL MEDIA ENQUIRIES
[email protected]

GENERAL ENQUIRIES
TEL: +353 1 518 0200

 

Nominated Adviser
Shore Capital and Corporate Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom

Joint Broker
Shore Capital Stockbrokers Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom

Joint Broker
Stifel Nicolaus Europe Limited
150 Cheapside
London, EC2V 6ET
United Kingdom

Euronext Growth Adviser and Joint Broker
J & E Davy
Davy House
49 Dawson Street
Dublin 2
Ireland

Auditors
Grant Thornton
24-26 City Quay
Dublin 2
Ireland

Registrars
Link Asset Services
The Registry
34 Beckenham Road
Kent, BR3 4TU
United Kingdom

 

MAJOR SHAREHOLDERS

Major shareholders

Major shareholders are as follows (interest as at 1 June 2019).

NAME NUMBER OF SHARES PERCENTAGE OF ISSUED SHARE CAPITAL
Software AG-Stiftung 61,272,920 22.30%
Axa Framlington 26,940,370 9.80%
Raglan Road Capital 24,697,347 8.99%
Joseph Wiley 20,994,487 7.64%
Legal & General 14,250,000 5.19%
Amati 13,205,882 4.80%
Rory Nealon 9,664,623 3.52%
Alan Harris 8,869,090 3.23%

There are a total of 274,817,283 shares in issue and no shares held in treasury. Pursuant to the AIM Rules, and insofar as the Company is aware, as at 1 June 2019, 34.51% of the Company’s AIM securities were not in public hands.

Restrictions: there are no restrictions on the transfer of Ordinary Shares.
Takeover Code: the Company is subject to the City Code on Takeovers and Mergers.

 

Nominated Adviser
Shore Capital and Corporate Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom

Joint Broker
Shore Capital Stockbrokers Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom

Joint Broker
Stifel Nicolaus Europe Limited
150 Cheapside
London, EC2V 6ET
United Kingdom

Euronext Growth Adviser and Joint Broker
J & E Davy
Davy House
49 Dawson Street
Dublin 2
Ireland

Auditors
Grant Thornton
24-26 City Quay
Dublin 2
Ireland

Registrars
Link Asset Services
The Registry
34 Beckenham Road
Kent, BR3 4TU
United Kingdom